Etoricoxib/Tramadol Combination Shows Promise for Acute Low Back Pain Relief

A new fixed-dose combination (FDC) of etoricoxib查看药品详情 and tramadol查看药品详情 has shown promising results in relieving acute low back pain (搜索)搜索该疾病, according to a recent phase III clinical trial. The study, conducted at three clinical sites in Mexico, compared the efficacy and safety of etoricoxib 90 mg/tramadol 50 mg once daily to paracetamol查看药品详情 975 mg/tramadol 112.5 mg three times daily in adult patients with moderate to severe acute low back pain.

The primary outcome of the study was the change in pain intensity measured by the Visual Analog Scale (VAS). Secondary outcomes included assessments of disability using the Oswestry Disability Index (ODI) and the Roland-Morris Disability Questionnaire (RMDQ). The trial included 124 patients, with 61 randomized to the etoricoxib查看药品详情/tramadol查看药品详情 group and 63 to the paracetamol查看药品详情/tramadol group.

Superior Pain Reduction with Etoricoxib/Tramadol

The results indicated that the etoricoxib查看药品详情/tramadol查看药品详情 combination led to a greater reduction in pain intensity compared to the paracetamol查看药品详情/tramadol combination. On day 5 of treatment, the change in VAS score was -4.6 for the etoricoxib/tramadol group compared to -3.8 for the paracetamol/tramadol group (p=0.041). This statistically significant difference suggests a faster and more effective pain relief with the etoricoxib/tramadol combination.

Improved Disability Scores

Both treatment groups showed statistically significant improvements in disability scores as measured by the ODI and RMDQ questionnaires (p=0.001). However, the etoricoxib查看药品详情/tramadol查看药品详情 group demonstrated a trend towards greater improvement in the bothersomeness to perform daily activities, as determined by the RMDQ (p=0.068).

Opioid-Sparing Effect and Safety

The etoricoxib查看药品详情/tramadol查看药品详情 combination also demonstrated an opioid-sparing effect, with a 55.9% reduction in the daily dose of tramadol compared to the paracetamol查看药品详情/tramadol group. This is significant because it can lead to a lower incidence of opioid-related side effects such as nausea, vomiting, and drowsiness.

Regarding safety, 38 subjects reported at least one adverse event (AE). 16 patients (26.2%) were in etoricoxib查看药品详情/tramadol查看药品详情 group, and 22 (34.9%) were in paracetamol查看药品详情/tramadol group. The severity of the adverse events was greater in paracetamol/tramadol group compared to etoricoxib/tramadol (41.5 vs. 10.5%), this difference was considered statistically significant (p=0.002).

Multimodal Analgesia for Acute Low Back Pain

The study's findings support the use of multimodal analgesia, which involves combining drugs with different mechanisms of action to achieve synergistic or additive effects. Etoricoxib查看药品详情, a selective COX-2 (搜索)搜索该靶点 inhibitor, reduces pain and inflammation by inhibiting prostaglandin synthesis. Tramadol查看药品详情, an atypical synthetic opioid, relieves pain through opioidergic, noradrenergic, and serotonergic effects.

"The combination of etoricoxib查看药品详情/tramadol查看药品详情 provides effective pain relief through multimodal management due to the different mechanisms of action of its components, achieving a faster reduction in pain intensity compared to conventional therapy," the researchers noted.

Implications for Clinical Practice

The results of this study suggest that the fixed-dose combination of etoricoxib查看药品详情 and tramadol查看药品详情 could be a valuable therapeutic option for managing acute low back pain (搜索)搜索该疾病. Its faster onset of action, opioid-sparing effect, and favorable safety profile may lead to improved treatment adherence and better patient outcomes. Further research is warranted to confirm these findings and explore the long-term benefits of this combination therapy.